Efficacy and resistance of different artemisinin-based combination therapies: a systematic review and network meta-analysis

• Published in: Parasitology international Vol. 74; p. 101919
• Main Authors: Mathenge, Peterson Gitonga, Low, Soon Khai, Vuong, Nguyen Lam, Mohamed, Muawia Yousif Fadlelmola, Faraj, Hazem Abdelkarem, Alieldin, Ghada Ibrahim, Al khudari, Rawan, Yahia, Nusaiba Adam, Khan, Adnan, Diab, Omar Mohammad, Mohamed, Yara Mahmoud, Zayan, Ahmad Helmy, Tawfik, Gehad Mohamed, Huy, Nguyen Tien, Hirayama, Kenji
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.02.2020
• Subjects: Antimalarials - therapeutic use; Artemisinin combination therapy; Artemisinins - therapeutic use; Asia, Southeastern; Cross-Sectional Studies; Drug Resistance; Drug Therapy, Combination; Efficacy; Humans; Malaria; Malaria, Falciparum - drug therapy; Network Meta-Analysis; Plasmodium falciparum - drug effects; Recrudescence; Resistance; Treatment Failure; Asia, Southeastern; Resistance; Artemisinin combination therapy; Efficacy; Treatment failure; Recrudescence; Malaria
• ISSN: 1383-5769; 1873-0329
• DOI: 10.1016/j.parint.2019.04.016

Malaria parasites have developed resistance to most of the known antimalarial drugs in clinical practice, with reports of artemisinin resistance emerging in South East Asia (SEA). We sort to find the status of artemisinin resistance and efficacy of different modalities of the current artemisinin-based combination therapies (ACTs). We carried out a systematic search in 11 electronic databases to identify in vivo studies published between 2001 and 2017 that reported artemisinin resistance. This was then followed by A network meta-analysis to compare the efficacy of different ACTs. Quality assessment was performed using the Cochrane Risk of Bias (ROB) tool for randomized controlled trials and National Institute of Health (NIH) tool for cross-sectional studies. The study protocol was registered in PROSPERO under number CRD42018087574. With 8400 studies initially identified, 82 were eligible for qualitative and quantitative analysis. Artemisinin resistance was only reported in South East Asia. K13 mutation C580Y was the most abundant mutation associated with resistance having an abundance of 63.1% among all K13 mutations reported. Although the overall network meta-analysis had shown good performance of dihydroartemisinin piperaquine in the early years, a subgroup analysis of the recent years revealed a poor performance of the drug in relation to recrudescence, clinical failure and parasitological failure especially in the artemisinin resistant regions. With report of high resistance and treatment failure against the leading artemisinin combination therapy in South East Asia, it is imperative that a new drug or a formulation is developed before further spread of resistance. [Display omitted] •Kelch 13 C580Y mutation, shown to be the dominant mutation associated with Artemisinin resistance.•Dihydroartemisinin piperaquine failure, in south east Asia leaves the fight against malaria with no better working drug.•Artemisinin resistance is confined in South East Asia.•Urgent need for a new drug or formulation against artemisinin resistance malaria.